NCT00857675 - A Efficacy and Safety Study of Adefovir Dipivoxil to Treat Chinese Patients With HBeAg+ve Chronic Hepatitis B | Biotech Hunter

Enrollment

480

Participants

Timeline

Start Date

December 31, 2002

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions

Chronic Hepatitis B

Interventions

DRUG

AAAA

Adefovir Dipivoxil (12 weeks) + open lable Adefovir Dipivoxil (28 weeks) + Adefovir Dipivoxil (12 weeks) + Open label Adefovir Dipivoxil (52-260weeks)

DRUG

AAPA

Adefovir Dipivoxil (12 weeks) + Open label Adefovir Dipivoxil (28 weeks) + placebo (12 weeks) + open label-Adefovir Dipivoxil (52-260 weeks)

DRUG

PAAA

Placebo (12 weeks) + Open label Adefovir Dipivoxil (28 weeks) + Adefovir Dipivoxil (12 weeks) + Open label Adefovir Dipivoxil (52-260 weeks)

Trial Locations (10)

100011

GSK Investigational Site, Beijing

100044

GSK Investigational Site, Beijing

130021

GSK Investigational Site, Changchun

200040

GSK Investigational Site, Shanghai

310003

GSK Investigational Site, Hangzhou

400038

GSK Investigational Site, Chongqing

GSK Investigational Site, Chongquin

510515

GSK Investigational Site, Guangzhou

510630

GSK Investigational Site, Guangzhou

Unknown

GSK Investigational Site, Jinan